UBS analyst Ashwani Verma raised the firm’s price target on Exelixis (EXEL) to $43 from $38 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target raised to $40 from $29 at Barclays
- Pan-Tumor Rollover Study: A New Horizon in Cancer Treatment
- RBC downgrades Exelixis on valuation ahead of Cabometyx cliff
- Exelixis downgraded to Sector Perform from Outperform at RBC Capital
- Truist biotech analyst holds an analyst/industry conference call